19:45 , Mar 31, 2017 |  BC Week In Review  |  Company News

Agalimmune, BioLineRx deal

BioLineRx acquired cancer company Agalimmune for $3 million in cash and $3 million in BioLineRx shares up front, plus undisclosed milestones. Agalimmune's lead compound AGI-134 is slated to begin clinical testing to treat solid tumors...
18:44 , Nov 4, 2016 |  BioCentury  |  Emerging Company Profile

Exploiting alpha-GAL

By coating tumor cells with a synthetic carbohydrate, Agalimmune Ltd. can enlist naturally circulating polyclonal antibodies to destroy primary solid tumor cells and stimulate an adaptive immune response against metastases. The newco’s Alphaject therapies are...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Alpha-gal glycolipids: Phase I data

A Phase I trial in 9 patients with unresectable metastatic melanoma with >=1 resectable cutaneous, subcutaneous or palpable lymph node metastasis showed that 2 intratumoral injections of alpha-gal glycolipids given 4 weeks apart were well...